AOTI INC (AIM: AOTI), a medical technology group focused on durable wound healing and amputation prevention, announced that topical oxygen therapy has been included in updated National Institute for Health and Care Excellence (NICE) guidelines for diabetic foot problems. The guidance recommends its use as an adjunct treatment for ulcers not responding to standard care.

The update follows NICE's exceptional surveillance review of its diabetic foot prevention and management guideline and recognises the clinical value of AOTI's Topical Wound Oxygen (TWO2) therapy. The recommendation comes earlier than expected, enhancing the company's market position in the UK.

TWO2 therapy has also been added to NHS Supply Chain's Advanced Wound Care Framework, providing Trusts, Integrated Care Boards and community care organisations with a compliant procurement route. This enables AOTI to accelerate marketing and expand access to the therapy's clinically proven and cost-effective benefits.

While the development is not expected to materially affect financial results for the current year, it strengthens AOTI's growth prospects in the UK wound care market. Founded in 2006 and headquartered in Oceanside, California and Galway, Ireland, AOTI has secured regulatory approvals for TWO2 therapy across multiple markets, including the US, Europe, UK, Canada, China, Australia, Saudi Arabia and Germany.